title: Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.
abstract: Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
authors.affiliation: U.O. Neurologia II, Centro Studi Sclerosi Multipla, Ospedale di Gallarate, Gallarate, Italy. angelo.ghezzi@aogallarate.it
authors.forename: A
authors.initials: A
authors.lastname: Ghezzi
authors.forename: L M E
authors.initials: LM
authors.lastname: Grimaldi
authors.forename: M G
authors.initials: MG
authors.lastname: Marrosu
authors.forename: C
authors.initials: C
authors.lastname: Pozzilli
authors.forename: G
authors.initials: G
authors.lastname: Comi
authors.forename: A
authors.initials: A
authors.lastname: Bertolotto
authors.forename: M
authors.initials: M
authors.lastname: Trojano
authors.forename: P
authors.initials: P
authors.lastname: Gallo
authors.forename: R
authors.initials: R
authors.lastname: Capra
authors.forename: D
authors.initials: D
authors.lastname: Centonze
authors.forename: E
authors.initials: E
authors.lastname: Millefiorini
authors.forename: S
authors.initials: S
authors.lastname: Sotgiu
authors.forename: V
authors.initials: V
authors.lastname: Brescia Morra
authors.forename: M P
authors.initials: MP
authors.lastname: Amato
authors.forename: A
authors.initials: A
authors.lastname: Lugaresi
authors.forename: G
authors.initials: G
authors.lastname: Mancardi
authors.forename: D
authors.initials: D
authors.lastname: Caputo
authors.forename: E
authors.initials: E
authors.lastname: Montanari
authors.forename: L
authors.initials: L
authors.lastname: Provinciali
authors.forename: L
authors.initials: L
authors.lastname: Durelli
authors.forename: R
authors.initials: R
authors.lastname: Bergamaschi
authors.forename: P
authors.initials: P
authors.lastname: Bellantonio
authors.forename: M R
authors.initials: MR
authors.lastname: Tola
authors.forename: S
authors.initials: S
authors.lastname: Cottone
authors.forename: G
authors.initials: G
authors.lastname: Savettieri
authors.forename: G
authors.initials: G
authors.lastname: Tedeschi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab